PHASE 1/2 STUDY USING ENB-003, A FIRST-IN-CLASS SELECTIVE ETBRI, IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED REFRACTORY SOLID TUMORS

被引：1
|
作者：
Jamal, Sumayah [1 ]
Nagrial, Adnan [2 ]
Joshua, Anthony [3 ]
Eek, Richard [4 ]
Jamal, Sumayah [1 ]
机构：
[1] ENB Therapeut Inc, New York, NY USA
[2] Blacktown Canc & Haematol, Blacktown, NSW, Australia
[3] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia
[4] Border Med Oncol Res Unit, Albury, NSW, Australia
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2020年 / 8卷
关键词：
D O I：
10.1136/jitc-2020-SITC2020.0803
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
803
引用
收藏
页码：A480 / A481
页数：2
相关论文
共 50 条
  • [41] First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.
    Yap, Timothy A.
    Barve, Minal A.
    Gainor, Justin F.
    Weekes, Colin D.
    Bockorny, Bruno
    Ju, Yawen
    Faucette, Ryan
    Bilic, Sanela
    Lee-Hoeflich, Si Tuen
    Song, Guochen
    Chyung, Yung
    Legler, Michelle
    Gan, Lu
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.
    Dasari, Arvind
    Kauh, John S.
    Tucci, Christopher
    Nanda, Shivani
    Kania, Marek K.
    Carlisle, Jennifer W.
    Paulson, Andrew Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] A PHII STUDY OF BEMCENTINIB, A FIRST-IN-CLASS SELECTIVE AXL KINASE INHIBITOR, IN COMBINATION WITH PEMBROLIZUMAB IN PTS WITH PREVIOUSLY-TREATED ADVANCED NSCLC: UPDATED CLINICAL & TRANSLATIONAL ANALYSIS
    Spicer, James
    Helland, Aslaug
    Carcereny, Enric
    Arriola, Edurne
    Domine Gomez, Manuel
    Trigo Perez, Jose Manuel
    Thompson, Jonathan
    Strauss, James
    Ortega Granados, Ana Laura
    Felip, Enriqueta
    Schmidt, Emmett
    Chisamore, Michael
    Madeleine, Noelly
    Rayford, Austin
    Lorens, Katherine
    Siddiqui, Abdul
    Gabra, Hani
    Nautiyal, Jaya
    Micklem, David
    Lorens, James
    Krebs, Matthew
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A221 - A221
  • [44] A phase I extension study of BBI608, a first-in-class cancer stein cell (CSC) inhibitor, in patients with advanced solid tumors
    Jonker, Derek J.
    Stephenson, Joe
    Edenfield, William Jeffery
    Supko, Jeffrey G.
    Li, Youzhi
    Li, Wei
    Hitron, Matthew
    Leggett, David
    Kerstein, David
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] A phase I study to evaluate the T-cell engager AMV564 alone and in combination with pembrolizumab in subjects with advanced solid tumors.
    Starodub, Alexander
    Piha-Paul, Sarina Anne
    Karim, Raghad
    Ruegg, Curtis
    Smith, Victoria
    Chun, Patrick Youngwhan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [46] Biomarker analyses from a phase I study of WNT974, a first-in-class Porcupine inhibitor, in patients (pts) with advanced solid tumors
    Rodon, Jordi
    Argiles, Guillem
    Connolly, Roisin M.
    Vaishampayan, Ulka
    de Jonge, Maja
    Garralda, Elena
    Giannakis, Marios
    Smith, David C.
    Dobson, Jason R.
    McLaughlin, Margaret
    Seroutou, Abdelkader
    Ji, Yan
    Dolan, Sinead
    Morawiak, Jennifer
    Moody, Susan
    Janku, Filip
    CANCER RESEARCH, 2018, 78 (13)
  • [47] Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
    Yap, Timothy A.
    O'Carrigan, Brent
    Penney, Marina S.
    Lim, Joline S.
    Brown, Jessica S.
    Luken, Maria J. de Miguel
    Tunariu, Nina
    Perez-Lopez, Raquel
    Rodrigues, Daniel Nava
    Riisnaes, Ruth
    Figueiredo, Ines
    Carreira, Suzanne
    Hare, Brian
    McDermott, Katherine
    Khalique, Saira
    Williamson, Chris T.
    Natrajan, Rachael
    Pettitt, Stephen J.
    Lord, Christopher J.
    Banerji, Udai
    Pollard, John
    Lopez, Juanita
    de Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (27) : 3195 - +
  • [48] IPI-549-01-A phase 1/1b first in human study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with pembrolizumab in subjects with advanced solid tumors
    Tolcher, Anthony W.
    Hong, David S.
    Sullivan, Ryan J.
    Mier, James Walter
    Shapiro, Geoffrey
    Pearlberg, Joseph
    Brail, Les H.
    Kharidia, Jahnavi
    Han, Lixin
    Ullmann, Claudio Dansky
    Stern, Howard Marvin
    Wolchok, Jedd D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [49] A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of unclear export (SINE) in patients (pis) with advanced solid tumors
    Mau-Soerensen, Morten
    Razak, Albiruni R. A.
    Shields, Anthony Frank
    Gabrall, Nashat Y.
    Gereeltano, John F.
    Shacham, Sharon
    Lassen, Ulrlk Niels
    Rashal, Taml
    Cooksoy, Jennifer
    Landosman, Yosof
    Pond, Gregory
    Oza, Amit M.
    Kauffman, Michael
    Siu, Lillian L.
    Bedard, Philippe L.
    Mahaseth, Hemchandra
    Mlrza, Mansoor Raza
    Mahipal, Arnit
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.
    Champiat, Stephane
    Cassier, Philippe A.
    Kotecki, Nuria
    Korakis, Iphigenie
    Vinceneux, Armelle
    Jungels, Christiane
    Blatchford, Jon
    Elgadi, Mabrouk M.
    Clarke, Nicole
    Fromond, Claudia
    Poirier, Nicolas
    Vasseur, Berangere
    Marabelle, Aurelien
    Delord, Jean-Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345